Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs . Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults .
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.
• Treatment of symptomatic gastroesophageal reflux disease (GERD) in
patients 1 year of age and older
• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in
patients 1 month of age and older
• Maintenance of healing of EE due to acid-mediated GERD in patients 1
year of age and older
• Pathologic hypersecretory conditions in adults
Parexel, George, South Africa
Parexel/Qdot Pharma, Port Elizabeth, South Africa
Renji Hospital, Shanghai, China
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
National Cheng Kung University Hospital, Tainan, Taiwan
Spaulding Clinical Research, West Bend, Wisconsin, United States
BC Children's Hospital, Vancouver, British Columbia, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.